Animal studies have shown that the anti-angina drug ranolazine can significantly reduce the number of deaths from arrhythmias - irregular or abnormally paced heartbeats - that have been triggered by carbon monoxide.
The findings could have important implications for the development of a protective treatment for adults and children who have been exposed to toxic levels of the gas.
"When patients are admitted to hospital with carbon monoxide poisoning, the main problem doctors face is preventing damage to the body whilst the body slowly removes the chemical," said University of Leeds' Professor Chris Peers, who led the research. "We've shown that ranolazine can rapidly protect the heart and prevent the kind of cardiac events which threaten patients long after their exposure to the gas."
Carbon monoxide poisoning causes 1.6 million deaths worldwide every year. Many people who have been exposed to the gas develop cardiac arrhythmias, which if left untreated can lead to a fatal cardiac arrest.
Until now, however, the underlying biochemical mechanisms causing damage to the heart have not been fully understood, preventing the development of effective treatments.
Ranolazine, which is sold under the trade name Ranexa, was approved in 2006 in the US for the treatment of angina. The drug works by targeting a sodium channel in the heart - the same channel that can also induce irregular heartbeats.
Researchers at the University of Leeds examined the effect of ranolazine in single cardiac cells, to learn why carbon monoxide can trigger arrhythmias. They found that exposure to the gas caused a key membrane channel carrying sodium ions through the heart to stay open for longer. This in turn caused calcium to build up within cells, with the combined effect altering the heart's regular cycle.
Colleagues at the Université Montpellier 1 and Université de Avignon in France then trialled ranozaline on rats exposed to carbon monoxide, to test its protective effects. They found that the drug markedly reduced the chance of arrhythmia in the animals.
"Whilst the link between arrhythmias and carbon monoxide has been known for over 50 years, this is the first piece of research to explain the underlying process," said the Faculty of Biological Sciences' Professor Derek Steele, who co-authored the research. "At the molecular level, we have shown that the mechanism underlying this adverse effect of carbon monoxide is a rise in the level of nitric oxide within cells, which in turn alters the function of the sodium channel."
The findings may also help those living in built-up areas or whose work involves daily exposure to lower levels of carbon monoxide, such as firefighters, the researchers believe. A recent and extensive epidemiological study of nine million people in the US showed a clear link between environmental carbon monoxide exposure and hospitalisation due to cardiovascular complaints. As ranolazine is a daily medication for angina, the researchers suggest it may be suitable to protect patients from the harmful effects of chronic exposure, though human clinical trials will be required to confirm this.
"The next step will be to replicate these findings in human trials. As the drug has been clinically approved, roll out of this treatment could begin soon after we have these results," said Professor Peers.
Dr Hélène Wilson, Research Advisor at the British Heart Foundation (BHF), which co-funded the study, said: "This study is a good example of research being used to better understand the underlying causes of an abnormal heart rhythm and in this case it has uncovered the ability of an old drug to perform a new trick. Carbon monoxide poisoning is tragically common but hopefully these promising results can be replicated in people so that it saves lives in the future."
The research is funded by the BHF, Gilead Sciences, the Wellcome Trust and Fondation de France. The paper will be published in the American Journal of Respiratory and Critical Care Medicine.
Andrew Macdonald, Yorkshire Kidney Research Fund (Jul 2016), £108,285
Amanda Bretman, Leverhulme Trust
(Jul 2016), £107,128
Zarah Timsah, Wellcome Trust
(Jul 2016), £100,000
Adrian Whitehouse, Worldwide Cancer Research (Jul 2016), £107,570
Roman Tuma, BBSRC (Jul 2016), £107,433
Helen Miller, Innovate UK (Jun 2016), £109,647
Adrian Goldman, Royal Society
(Jun 2016), £250,000
James Deuchars, Dunhill Medical Trust (Jun 2016), £107,247
Keith Hamer, DEFRA Dept for Env. Food & Rural Affairs
(Jun 2016), £103,887
Richard Bayliss, EU - European Union
(Jun 2016), £108,176
Jamel Mankouri, British Lung Foundation
(Jun 2016), £105,557
Jamel Mankouri, John Barr, British Lung Foundation
(Jun 2016), £24,000
Zahra Timsah, Wellcome Trust (Jun 2016), £108,605
Andrew Macdonald, Kidney Research Fund UK
(Jun 2016), £108,110
Andrew MacDonald, Richard Foster, Stephen Griffin, Kidney Research Fund UK
(Jun 2016), £63,653
Edwin Chen, Academy of Medical Sciences (Jun 2016), £108,131
Edwin Chen, Academy of Medical Sciences
(Jun 2016), £98,110
Adrian Goldman, Royal Society (May 2016), £106,738
Peter Stockley, Wellcome Trust (May 2016), £1,246,487
John Ladbury, Christopher Jones, Cancer Research UK
(May 2016), £6,905
Elton Zaqiraj, Wellcome Trust (May 2016), £1,093,823
Adrian Whitehouse, Julie Aspden, BBSRC (May 2016), £457,270
Alison Baker, Miller Camargo-Valero, BBSRC
(May 2016), £451,124
Peter Urwin, BBSRC (May 2016), £432,379
John Trinick, R Elwyn Issac, Leverhulme Trust
(May 2016), £171,742
, British Council, UK
(May 2016), £17,793
Mark Harris, Horserace Betting Levy Board
(Apr 2016), £10,000
Peter Stockley, Neil Ranson, Roman Tuma, David Rowlands, MRC (Apr 2016), £341,225
Jamel Mankouri, Royal Society (Apr 2016), £332,396
Andrew Tuplin, MRC (Apr 2016), £508,170
Keith Hamer, DEFRA Darwin Initiative (Apr 2016), £327,744
Simon Goodman, British Council, UK
(Mar 2016), £35,800
, British Council, UK
(Mar 2016), £12,802
Katie Field, NERC
(Mar 2016), £186,411
Isuru Jayasinghe, Royal Society
(Mar 2016), £14,919
William Hoppitt, EU (Feb 2016), £34,345
Helen Miller, ABNA Ltd (Feb 2016), £115,000
Sarah Calaghan, Isuru Jayasinghe, BHF (Jan 2016), £52,050
Edwin Chen, Wellcome Trust (Jan 2016), £98,341
Patricija Van Oosten-Hawle, Wellcome Trust (Jan 2016), £89,900
James Duce, Alzheimer's Society (Jan 2016), £84,834
Andrew Smith, Rosetrees Trust (Jan 2016), £20,000
Richard Bayliss, Cancer Research UK (Jan 2016), £10,000
Richard Bayliss, BBSRC (Jan 2016), £8,000
Richard Bayliss, MRC (Jan 2016), £8,000
Thomas Edwards and colleagues in the School of Chemistry, EPSRC (Jan 2016), £2,228,732
David Brockwell, Sheena Radford, BBSRC (Dec 2015), £358,570
Stephanie Wright, Kay Kendall Leukaemia Fund (Dec 2015), £207,286
Stefan Kepinski, Michelle Peckham, BBSRC (Nov 2015), £461,760
Ryan Seipke, BBSRC (Nov 2015), £340,536
Paul Knox, BBSRC (Nov 2015), £40,000
Helen Miller, Agriculture & Horticulture Develpmnt Brd (Oct 2015), £63,560
Jessica Kwok, Wings For Life Spinal Cord Research (Oct 2015), £134,981
Joe Cockburn, Royal Society (Oct 2015), £14,960
Alison Ashcroft, Peter Stockley, Sheena Radford, Nicola Stonehouse, David Brockwell, Darren Tomlinson, BBSRC (Oct 2015), £340,937
Alan Berry, Wellcome Trust (Oct 2015), £752,365
Mark Harris, Thomas Edwards, John Barr and colleagues from the School of Chemistry, Wellcome Trust (Sep 2015), £204,959
Mark Harris, Royal Society (Sep 2015), £74,000
Zahra Timsah, Royal Society (Sep 2015), £15,000
Katie Field, Royal Society (Sep 2015), £14,700
Christine Foyer, Royal Society (Sep 2015), £12,000
Julie Aspden, MRC (Sep 2015), £633,020
Ian Hope, Marie-Anne Shaw, BBSRC (Aug 2015), £381,998
Helen Miller, ABNA Ltd (Aug 2015), £22,968
Alan Berry, Alex Breeze, Adam Nelson, BBSRC (Aug 2015), £479,490
Katie Field, BBSRC (Aug 2015), £830,381
Tim Benton, M & W MACK LTD (Aug 2015), £48,711
Neil Ranson, Mark Harris, Ade Whitehouse, Peter Stockley, Sheena Radford, Alan Berry, Wellcome Trust (Jul 2015), £1,000,000